SEAGULL HEALTH
Your health,We care!
Glumetinib features good oral absorption and stable metabolism in vivo, and it can easily penetrate the blood-brain barrier, making it suitable for patients with brain metastases.
AuthenticGuaranteeFast DeliveryPrivacy On March 8, 2023, Glumetinib was conditionally approved for marketing by the National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations.
In December 2023, Glumetinib was included in China’s National Medical Insurance Drug List.
On June 24, 2024, Glumetinib received marketing approval in Japan, emerging as the first domestically developed MET inhibitor to secure regulatory approval in both China and Japan. This milestone marks the international recognition of China’s innovative pharmaceuticals.
On March 8, 2023, the National Medical Products Administration (NMPA) announced that it had recently granted conditional marketing authorization for C···【Read More】
Update: 27 Jan,2026Source: Haiou HealthViews: 128
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
